Zorifertinib for EGFR-mutant Advanced NSCLC with CNS Metastases

This study investigates the potential benefits of using zorifertinib as the first treatment option for patients with a specific type of advanced lung cancer called non-small cell lung cancer (NSCLC), which has spread to the brain. The study focuses on patients whose cancer shows mutations in the epidermal growth factor receptor (EGFR), a common target in cancer treatment. By comparing zorifertinib to other similar treatments, the study aims to understand if it can improve survival rates and safety for these patients. This is important because finding effective treatments for this type of cancer can significantly improve quality of life and outcomes for patients. Participants in this study receive zorifertinib and are monitored over time to measure how long they live after starting the treatment, regardless of the cause of death. This measurement, called overall survival, helps determine the effectiveness of the treatment. The study takes place across multiple centers and involves different groups of patients to ensure comprehensive results. Safety and potential side effects are also closely observed to ensure the treatment is both effective and safe for patients.